This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

| More on:
A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Universal Biosensors, Inc (ASX: UBI) shares are having a day to remember on Tuesday.

At the time of writing, the ASX healthcare stock is up 72% to 27.5 cents.

Why is this ASX healthcare stock jumping?

Investors have been fighting to get hold of the medical device company's shares after it made a major announcement.

According to the release, Universal Biosensors has received FDA 510(k) and CLIA Waiver approval for its Xprecia Prime Coagulation Analyzer as a Class II device.

The Xprecia Prime Coagulation Analyzer is Universal Biosensors' second generation, new and improved coagulation monitoring device. Xprecia Prime fits into your palm, is portable, accurate, and easy to use.

The company advised that this approval allows it to sell Xprecia Prime into health care professional settings such as hospitals, clinics, and doctor's offices in the USA.

'Historic moment'

The ASX healthcare stock's CEO, John Sharman, was delighted with the news. He said:

Approval to sell Xprecia Prime in the USA is a historic moment for UBI. It represents more than 10 years of research & development work and many millions of dollars of investment.

Sharman also highlights that this is the first time a coagulation device has been granted a CLIA Waiver. He adds:

This is the first time the FDA have granted a CLIA Waiver by Application to any coagulation device, and it is testament to the performance of Xprecia Prime. The number of PT/INR tests performed in clinics is the largest part of the USA market so to have won unrestricted access to all clinics and hospitals across the USA is a major achievement.

What now?

Sharman notes that the product has a huge addressable market and that revenue generation could be on way. He explains:

There are more than 6 million patients who take warfarin (coumadin) in the USA1 and more than 140 million2 PT/INR test strips are sold each year. This FDA approval represents the first opportunity in UBI's history to access the lucrative (and fully reimbursed) USA market.

Our expectation is Xprecia Prime will qualify under the existing reimbursement codes used by Medicare, Medicaid and USA Health insurers. UBI has a pipeline of sales and distribution contracts already in negotiation and now that we have FDA approval we expect to conclude some, if not all of these contracts, win market share and generate substantial revenue for the company.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Happy healthcare workers in a labs
Healthcare Shares

Up 74% in 6 months, guess which ASX 200 healthcare stock just hit another all-time high

This company has busily deployed cash over the past six months while growing at a phenomenal pace.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Broker says this ASX biotech stock could almost double in value

Bell Potter is feeling very bullish about this risky stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Share Gainers

If you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now!

Mesoblast shares have been on a tear this past month. But why?

Read more »

Woman going for a scan reassured by doctor
Healthcare Shares

How AI could boost this ASX 300 healthcare stock

The Firetrail investment management team see AI providing a 'material tailwind' for this stock.

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is the ResMed share price diving 5% today?

Weight loss wonder drugs are weighing heavily on this stock.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Why is the Telix share price jumping 15% to a record high?

This healthcare stock is scaling new heights on Thursday. But why?

Read more »

Stressed thoughtful old female general practitioner doctor physician looking in distance, considering difficult medical problem solution or illness treatment, working on computer in clinic office.
Healthcare Shares

How much do you need to invest in CSL shares for $8,000 in annual dividends?

CSL's dividends are exponentially more valuable for long-term investors.

Read more »

smiling health care workers in a medical setting
Healthcare Shares

'Critical unmet need': Why everyone is talking about this ASX 200 healthcare stock

This healthcare stock has been given a boost from the US FDA today.

Read more »